Phase 1 Results for Imaging Agent Cu-61 NuriPro Shows Promise for Future Theranostic Option Cu-67

/in , , /by

At the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, a promising phase I clinical trial results were presented for Cu-61 NuriPro, a next-generation PET imaging agent specifically designed for patients with PSMA-positive metastatic prostate cancer. This agent targets prostate-specific membrane antigen (PSMA), a protein commonly overexpressed in prostate cancer cells, making […]

Read more

DiWB-1: A Targeted Approach to Prostate Cancer Treatment

/in , /by

DiWB-1, a luteinizing hormone-releasing hormone (LHRH)-targeted peptide-drug conjugate (PDC) with PI3K inhibition properties, is an emerging candidate that may offer a new way to treat prostate cancer. Its design and mechanism suggest potential for addressing some of the limitations of current treatments, particularly for resistant cases. DiWB-1 is described as an LHRH-targeted PDC, a class […]

Read more